A subanalysis of the PRIMA/ENGOT-OV26/GOG-3012 trial found that quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo.
A study of patients with gynecologic cancer and COVID-19 found that neither having cancer nor receiving treatment for it worsened COVID-19 outcomes.
Within this study, satisfaction was markedly higher in those treated with apixaban, and adherence rates appeared to be similar between both modalities in women undergoing surgery for gynecologic cancer.